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Summary 
Background: Adjuvant trastuzumab significantly improves outcomes in human epidermal 
growth factor receptor 2 (HER2)-positive early breast cancer (EBC). The standard duration is 
12 months but shorter treatment could provide similar efficacy whilst reducing toxicities 
and cost. 
Methods: We randomly assigned patients with HER2 positive EBC to receive either 6-
months or 12-months trastuzumab, in a phase 3 non-inferiority trial. Assuming a 4-year 
disease-free-survival (DFS) rate of 80% for the 12-month arm, 4000 patients were required 
to assess the non-inferiority of 6-months (5% 1-sided significance, 85% power), defining 
non-inferiority as no worse than 3% below the standard arm. A pre-planned, event-driven 
DFS analysis required 500 events. This trial is registered with EudraCT (2006-007018-39), 
ISRCTN (52968807), and ClinicalTrials.gov (NCT00712140). 
Findings: Between 4th October 2007 and 31st July 2015, 2045 patients were randomised to 
12-months trastuzumab and 2043 to 6-months. 69% had ER-positive disease; all patients 
received chemotherapy (85% as adjuvant treatment); 90% received anthracyclines (48% 
with taxanes) and 10% taxane-only combinations; 53% had trastuzumab sequentially after 
chemotherapy. At 5·4 years median follow-up with 335 (8%) deaths, and 512 (13%) DFS 
events, 4-year DFS rates were 89·4% (95%CI, 87·9-90·7) in the 6-month group and 89·8% 
(95%CI 88·3-91·1) in the 12-month group (Hazard Ratio 1·07; 90%CI 0·93–1·24, non-
inferiority p=0·01), demonstrating non-inferiority of 6-months trastuzumab. Congruent 
results were found for overall survival (OS) (non-inferiority p=0·001), and landmark analyses 
6 months from starting trastuzumab (non-inferiority p=0·02 (DFS) and p=0·02 (OS)). 6-
months trastuzumab resulted in fewer patients reporting severe adverse events (373/1939 
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(19%) versus 459/1894 (24%) 12-month patients, p=0·0002) or stopping early because of 
cardiotoxicity (61/1939 (3%) versus 146/1894 (8%) 12-month patients, p<0·0001). 
Interpretation: We have demonstrated 6-months trastuzumab is non-inferior to 12-months 
in HER2-positive EBC, with less cardiotoxicity and fewer severe adverse events. 
Funding: National Institute for Health Research, Health Technology Assessment Programme 
(grant number 06/303/98). 
 
Key Words: PERSEPHONE, trastuzumab duration, early breast cancer, HER2 positive, 
adjuvant therapy. 
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Introduction 
Trastuzumab given with chemotherapy in HER2-positive breast cancer in the metastatic1 
and adjuvant setting2-4 marked a paradigm shift in treatment with improved outcomes, and 
longer term follow-up has subsequently confirmed these benefits5,6. Twelve months of 
adjuvant trastuzumab was chosen arbitrarily for the pivotal licensing trials2-4 and 
subsequently became standard. However the FinHer trial, which randomised patients to 
adjuvant chemotherapy with or without 9 weeks concurrent trastuzumab, demonstrated 
significant improvement in disease-free survival7 and generated considerable interest in the 
possibility of shorter trastuzumab durations. Trastuzumab has well-recognised toxicities 
particularly cardiac8-11 and significant costs. Studies have been conducted to assess whether 
similar outcomes can be achieved with reduced treatment duration. PHARE (France)12, 
PERSEPHONE (UK)13 and the HORG study (Greece)14 compared 6 with 12 months. SHORTHer 
(Italy)15, and SOLD (International)16 compared 12 months with 9 weeks given concurrently 
with docetaxel-first sequenced chemotherapy, and E219817 compared 12 months with 12 
weeks given concurrently with weekly paclitaxel. Five of the six de-escalation trials were 
supported wholly or in part by government funding and aimed to discover the optimal 
balance between efficacy, toxicity and cost for patients and health services. The 
PERSEPHONE trial is based on the hypothesis that 6 months adjuvant trastuzumab is non-
inferior to 12 months in terms of outcomes, but with reduced toxicity and cost. The trial 
uses a non-inferiority design 18 and we report 4-year disease-free survival results, the 
definitive primary endpoint. 
 
METHODS 
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Study Design and Oversight 
PERSEPHONE was a prospective, multicentre, phase 3 randomised trial to test the 
hypothesis that 6 months of trastuzumab therapy is non-inferior to 12 months. The trial was 
approved by the Multi-Centre Research Ethics Committee (07/MRE08/35), Local Research 
and Development Departments at participating institutions, was sponsored by Cambridge 
University Hospital NHS Trust and University of Cambridge and co-ordinated and analysed 
by the Warwick Clinical Trials Unit at the University of Warwick. The trial was conducted in 
accordance with the Declaration of Helsinki, supported by the National Cancer Research 
Network (NCRN No 4078), and funded by the National Institute for Health Research (NIHR) 
Health Technology Assessment Programme (HTA), grant number 06/303/98. The trial 
recruited patients in 152 centres in the UK, under the auspices of an Independent Data 
Safety and Monitoring Committee (IDSMC), an Independent Trial Steering Committee (TSC), 
and a Trial Management Group (TMG).  
 
Participants 
Eligible patients, 18 years or older, had a histological diagnosis of invasive EBC with 
overexpression of HER2 receptor defined according to the ASCO/CAP Guidelines19. All 
patients had a clear indication for chemotherapy and at the start of the trial, following 
written informed consent, were randomised prior to starting trastuzumab. However, in 
2009 recruitment rate remained substantially lower than expected and after discussion 
between the TMG, TSC, IDMSC and funders, a protocol amendment (Protocol v.3.1 July 
2009) allowed randomisation to occur at any time up to and including the ninth cycle of 
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trastuzumab. All participants were considered medically fit to receive treatment by the 
responsible clinician. Female patients who were of child-bearing potential were non-
pregnant, non-lactating, and agreed to use adequate contraception during treatment. 
 
Randomisation and masking 
The trial was open label and patients were randomised (1:1) to either 12 months (standard - 
18 cycles) of trastuzumab or 6 months (experimental - 9 cycles) of trastuzumab (Figure 1).  
Randomisation was performed by telephone to the Warwick Clinical Trials Unit, where a 
central computerised minimisation procedure used the following stratification variables; 
oestrogen receptor (ER) status (positive: negative); chemotherapy (CT) type (anthracycline 
(A) without taxane (T):  A with T:  T without A: neither A nor T); CT timing (adjuvant (ACT): 
neoadjuvant (NACT)); and trastuzumab timing (concurrent: sequential). 
 
Procedures 
Trastuzumab was administered every 3 weeks either intravenously (IV) or, following a 
protocol amendment 
(https://warwick.ac.uk/fac/sci/med/research/ctu/trials/cancer/persephone/professionals Version 
4·0: 31st October 2013), sub-cutaneously (SC). Switching from IV to SC was allowed at 
clinician discretion. The IV loading dose was 8mg/kg followed by maintenance doses of 
6mg/kg, and the SC dose was fixed at 600mg.  
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After randomisation, patients were followed-up routinely at the centre where the patient 
was recruited or an associated institution with ethical approval for the study. Follow-up was 
every 12 weeks for the first year after starting trastuzumab, recording all toxicities 
experienced. Common Toxicity Criteria Adverse Events (CTCAE version 3) grades were 
recorded for each trastuzumab cycle after randomisation. Originally, 3-monthly left 
ventricular ejection fraction (LVEF) assessments for up to 12 months after starting 
trastuzumab were required in all patients. However in June 2013, the IDSMC recommended 
reducing LVEF monitoring to 4-monthly, in line with new national guidelines20. Trastuzumab 
was discontinued if LVEF fell below 50%, and then LVEF was re-checked after 6 and then 12 
weeks. Trastuzumab was restarted with recovery of LVEF, however if treatment could not 
be restarted for 12 weeks because of persistently low LVEF, it was stopped permanently. 
Follow-up was carried out 6-monthly for the second year and annually thereafter, in 
accordance with standard local practice and continued for 10 years. 
 
Outcomes 
The primary endpoint of DFS was calculated from the date of diagnostic biopsy to date of 
first invasive breast cancer relapse (local or distant) or death, or to date of censor in patients 
alive and relapse-free. Overall survival (OS) was also calculated from the date of diagnostic 
biopsy. Additional analyses of disease-free interval (DFI), distant DFI (DDFI), distant DFS 
(DDFS), invasive DFS (IDFS) (including contralateral breast and second primary cancers - IDFS 
according to the STEEP system21), and breast-cancer specific survival (BCSS) were carried 
out. Since randomisation could occur at any time up to and including the ninth cycle of 
trastuzumab, a landmark analysis was carried out from 6 months after the start of 
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trastuzumab. The number of trastuzumab cycles received per patient was recorded, with 
route of administration and reasons for any deviation from protocol. LVEF measurements 
were defined as low if results were <50% or reported as low without quantification of LVEF. 
Incidence of clinical cardiac dysfunction, defined as symptoms or signs of congestive heart 
failure or new cardiac medication, was recorded every 3 months for 12 months. A 
cardiologist (CP) was a member of the trials group and reviewed the cardiac toxicity 
together with the CI (HME) and other members of trial management group. 
 
The Quality of Life assessment schedule specifies assessments before starting trastuzumab, 
and then 3, 6, 9, 12, 18 and 24 months later.  All patients followed this schedule from the 
time they entered the trial, completing assessments at the same time-points in their 
treatment but, if randomised part way through their trastuzumab treatment, with the 
omission of the missed baseline +/- 3-month time-point. Questions regarding general health 
and the EuroQoL EQ-5D-3L were recorded. Health economic analysis will be reported 
separately. 
 
Statistical Analysis 
The trial was designed to assess non-inferiority of the experimental group (6 months 
trastuzumab), and the clinically acceptable non-inferiority margin for the 6 month group 
was defined as being not worse than 3% absolute below the 4-year DFS of the standard 
group (12 months trastuzumab). This 3% non-inferiority margin was decided before the start 
of the trial following consensus from the trial development group together with the patient 
and public involvement group. Data from adjuvant trastuzumab trials at the time2-4 
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estimated the 4-year DFS for patients treated with 12 months trastuzumab to be 80%. 
Consequently, 4000 patients (2000 in each group) were required to demonstrate the non-
inferiority of 6 months’ trastuzumab with a 3% non-inferiority margin of the 4-year DFS, 
with 5% 1-sided significance, and 85% power. This assumes a 4-year recruitment period, an 
additional 5 years follow-up and 4% lost-to-follow-up rates. Survival curves were plotted 
using Kaplan-Meier methodology and the hazard ratio (HR) between the two arms was 
estimated using a Cox’s proportional hazards model containing only the trial treatment 
effect, after graphical checks for proportionality of hazards. The upper limit of the HR 
required to demonstrate the 3% non-inferiority was only to be calculated at the time of 
analysis, and based on the DFS in the 12-month arm observed at the time of analysis. As 
described in Mauri and D’Agostino 22 if the upper limit of the 90% confidence interval (the 
95th percentile)  of the estimated HR was less than the relevant 3% absolute non-inferiority 
limit, then the experimental group (6-months trastuzumab) would be regarded as non-
inferior. 
 
Warwick Clinical Trials Unit carried out all analyses using SAS v9·4 software. The IDSMC 
approved statistical analysis plan (SAP) stated that the event-driven primary endpoint 
analysis required 500 DFS events to have occurred. At this point, the relevant non-inferiority 
limits in terms of HR for 3% non-inferiority in DFS were calculated using the observed 4-year 
DFS rates in the standard, 12-month group. The SAP included a secondary analysis adjusting 
for stratification and baseline prognostic factors and also the presentation of treatment 
effect on DFS for each stratification variable using hazard ratio plots23. To remove the effect 
of timing of randomisation, the SAP also defined an exploratory landmark analysis for 
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patients alive and disease-free 6 months after starting trastuzumab. All randomised patients 
were included in all analyses where possible and were analysed on an intention-to-treat 
(ITT) basis since the trial aimed to compare durations of trastuzumab in routine clinical 
practice. PERSEPHONE is registered with EudraCT (2006-007018-39), ISRCTN (52968807), 
and ClinicalTrials.gov (NCT00712140). 
 
Role of the funding source 
The funder of the study (NIHR HTA) had no role in study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author had full 
access to all the data and, along with LH and JD, had final responsibility for the decision to 
submit for publication with the agreement of all the authors and the data monitoring and 
safety committee. The views expressed are those of the authors and not necessarily those 
of the NHS, the NIHR or the Department of Health and Social Care. 
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RESULTS 
A total of 4089 patients were randomised by 210 clinicians at 152 sites in the UK between 
4th October 2007 and 31st July 2015. One double randomisation reduced the analysis set to 
4088 patients (Figure 1). Nineteen patients were deemed ineligible (7, 12-month patients: 
12, 6-month patients), principally for previous cancers or DCIS treated by radiotherapy as 
well as surgery. Patient characteristics including minimization and other prognostic variables 
were balanced across the two groups (Table 1). Sixty-nine percent of patients had ER 
positive tumours; 58% of ACT patients were node negative, and 47% of ACT patients had 
tumours <2cm. Randomisation before the start of trastuzumab occurred in 44% of patients 
and the timings for those randomised after the first cycle of trastuzumab are shown in 
appendix p1. Among NACT patients (n=620), 89% received A and T, 9% A without T, 2% T 
without A; corresponding percentages for ACT (n= 3468) were 41%, 48% and 11% (appendix 
p1). UK standard practice gradually changed during trial recruitment with a steady increase 
in anthracycline and taxane combinations, trastuzumab commencing concurrently with 
taxanes but not anthracyclines, taxane-based treatment without anthracyclines and 
neoadjuvant timing (appendix p2). Patients given trastuzumab and chemotherapy 
concurrently compared with sequentially were more often node positive (53% and 32% 
respectively), had larger tumours (> 2cms: 55% v 47% respectively), received neoadjuvant 
treatment (26% v 6% respectively) and in addition had shorter median duration of follow-up 
(4·5 years v 5·8 years) (appendix pp2-5). 
 
Complete trastuzumab administration details are available for 3836/4088 (94%) patients; 
93% 12-month patients and 95% 6-month patients (Figure 1). Eighty-two percent 
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(40,530/49,632) of trastuzumab cycles were administered IV and 18% (9,102/49,632) SC. In 
total 3294/3836 (86%) patients received the protocol specified number of trastuzumab 
cycles; 1556/1895 (82%) 12-month patients and 1738/1941 (90%) 6-month patients. The 
most common reasons for early treatment cessation were cardiac toxicity (146/1894 (8%) 
12-month patients, 61/1939 (3%) 6-month patients) and patient request (91/1894 (5%) 12-
month patients, 24/1939 (1%) 6-month patients). Delays occurred in 3631/49,632 (7%) 
cycles (appendix p4), the main reasons being holidays (n=827 (23%)), sepsis/infection 
(n=184 (5%)) and cardiotoxicity (n=178 (5%)). The commonest chemotherapy treatments 
(known for 3959 patients), were fluorouracil, epirubicin, cyclophosphamide, with docetaxel 
(FEC-T) (12-month: 811/1985 (41%); 6-month: 790/1974 (40%)) and FEC (12-month: 
548/1985 (28%); 6-month: 567/1974 (29%)). 
 
At database lock on 17 April 2018, with a median follow-up of 5·4 years (IQR 3·6-6·7 years) 
and 96% of alive patients followed up for at least 2 years, 335 deaths (8% of the 4088 
patients) had been reported, 81% due to breast cancer (Table 2). Local or distant relapse 
occurred in 452 (11%) patients, with distant metastases (373 patients) occurring in the liver 
(160 patients (43%)), bone (142 patients (38%)), lung (139 patients (37%)), and brain (78 
patients (21%)). A relapse or death was reported for 512 patients (13%). 
 
The 4-year DFS rate in the 12-month group was 89·8% (95% confidence interval (CI) 88·3-
91·1) and 89·4% (95% CI 87·9-90·7) in the 6-month group (Figure 2A). Thus, with the non-
inferiority margin of 3%, the non-inferiority limit for the hazard ratio (HR) was set at 1·32. 
The HR for relapse or death with 6 months compared to 12 months trastuzumab was 1·07 
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(90%CI 0·93, 1·24); this outcome met the pre-specified definition of non-inferiority (non-
inferiority p=0·01). The two-sided p-value for difference between treatments was 0·42. 
Adjustment for all stratification factors gave the same results with a HR of 1·07 (90%CI 0·93, 
1·24; non-inferiority p=0·01). Analysis of OS (Figure 2B) also met the pre-specified definition 
of non-inferiority (4-year OS rate of 94·8% in the 12-month group, HR non-inferiority limit 
1·60, HR=1·14 (90%CI 0·95, 1·37), non-inferiority p=0·001). The two-sided p value for 
difference between treatments was 0·22, and adjusting for stratification factors found 
similar results (HR=1·13 (90%CI 0·94, 1·35)). 
 
Forest plots for DFS including all patients (Figure 3A) showed heterogeneity for 
chemotherapy type (p=0·01) predominantly driven by the small number of events in the 
taxane-only group, in which most patients received docetaxel with cyclophosphamide 25. 
The timing of trastuzumab relative to chemotherapy (concurrent/sequential) showed 
heterogeneity (p<0·001) favouring 12 months in patients receiving concurrent trastuzumab. 
Forest plots for OS (appendix p6) again showed heterogeneity for concurrent and sequential 
patients; they additionally showed heterogeneity for ER status (p=0·02), with patients with 
ER negative disease appearing to do better with 12 months trastuzumab. . No heterogeneity 
was observed for age, grade, menopausal status or IHC 3+:IHC2+/FISH positive in DFS or OS. 
Exploratory forest plots for adjuvant patients only (Figure 3B and appendix p7) showed 
similar results, with no heterogeneity for node status, size, and combined ER and node 
status.  
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The landmark analysis of DFS and OS included 4009 patients who remained alive and 
disease-free 6 months from starting trastuzumab. Similar results were found both for the 
landmark DFS (HR=1·07 (90%CI 0·92–1·24) non-inferiority p=0·02) and OS (1·13 (90%CI 0·94–
1·37) non-inferiority p=0·02) analyses (Figure 4). Congruent results were found for DFI, DDFI, 
DDFS, IDFS, and BCSS analyses (data not shown). Forest plots for landmark DFS and OS also 
showed similar results to those observed for DFS and OS (appendix pp8-11). 
 
During the 12-month period from starting trastuzumab a higher proportion of 12-months 
patients than 6-month patients reported at least one adverse event of severe grade 
(CTCAE>=3, or 2 for palpitations; 459/1894 (24%) vs 373/1939 (19%) respectively, p=0·0002) 
(Table 3). The excesses were in cough (4·3% v 2·3%: p=0·0005), palpitations (4·8% v 2·7%: 
p=0·0007), fatigue (11·9% v 8·6%: p=0·0009), pain (5·2% v 3·2%: p=0·003), chills (3·5% v 
2·1%: p=0·008), muscle/joint pains (11·4% v 9·0%: p=0·02), and nausea (1·8% v 1·0%: 
p=0·05) (appendix p12). These were seen predominantly during the 7-12 month period. 
Similarly, the number of serious adverse reactions (SARs) reported were 67 occurring in 64 
12-month patients and 34 occurring in 29 6-month patients, the excesses seen during the 7-
12 month period. Clinical cardiac dysfunction was reported more commonly in 12-month 
than 6-month patients (224/1968 (11%) vs 155/1994 (8%) respectively, p<0·0001) (Table 3). 
A small absolute difference was observed in the first 6 months (8% of 12-month patients, 
6% of 6-month patients, p=0·02), with a larger difference during the 7–12-month period (8% 
vs 5% respectively, p=0·0002). Trastuzumab was stopped early because of cardiac toxicity in 
146/1894 (8%) of 12 month patients and 61/1939 (3%) of 6 month patients (p<0·0001). 
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In total, 19,414 measurements of LVEF were made in 4078 patients; 10162 on 2040 12-
months patients and 9252 on 2038 6-month patients. During the first 6 months of 
treatment, proportions of patients with low LVEF were 7% in both groups (p=0·96). 
However, during months 7–12 this proportion increased for 12-month patients (8%) but fell 
for 6-month patients (5%) (p=0·0003 for difference between groups). During months 7 to 
12, significant falls of LVEF to <50% after a baseline of >=59% occurred in 4% of patients in 
the 12-month and 2% of patients in the 6-month group (p=0·001). Eleven deaths were 
considered cardiac (primary or contributory cause) however none occurred during 
trastuzumab and none were considered to be related to trastuzumab by the TMG (appendix 
p5). Comparing the 44% of patients randomised into the trial before the start of 
trastuzumab with all patients, the comparisons of toxicity between the two arms was 
broadly similar, although toxicity including cardiotoxicity showed marginally higher rates for 
both 6 and 12 months for patients randomised before the start of trastuzumab, (appendix p 
6 ).  
 
In total, 3910 patients (1960 12-month patients, 1950 6-month patients) participated in the 
QoL sub-study. In both groups, feelings of general health are seen to decline during the first 
three months of trastuzumab (appendix p14), when 47% of patients will have been receiving 
concurrent chemotherapy, and then steadily improve after completion of treatment. The EQ-
5D-3L health state is seen to remain steady from baseline to three months for both 
randomised groups, with a trend to slowly increasing after this, occurring slightly later for 
12-month patients (appendix p15).  
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DISCUSSION 
Adjuvant trastuzumab in HER2-positive EBC has improved the long-term outcome for this 
poor prognosis molecular subtype27, and twelve months treatment is currently the standard 
duration. In 2006, the FinHER trial7 demonstrated efficacy for a significantly shorter duration 
(9 weeks) compared with a no trastuzumab control arm and on the strength of this study 
the PERSEPHONE Trial was designed to test  6 months of trastuzumab against the standard 
duration of 12 months. Using an established design18, PERSEPHONE has demonstrated non-
inferiority for 6 months of trastuzumab compared with 12 months. Our definition of non-
inferiority was no worse than 3% absolute below the standard group’s 4-year DFS rate, and 
the non-inferiority limit was thus calculated as a hazard ratio (HR) of <1·32. Notably, the 
upper confidence limit of the HR was 1.24, which is significantly below this non-inferiority 
boundary. This reflects, that although the non-inferiority boundary was set at 3%, the actual 
point estimate reduction observed was very small at 0.4% for 4-year DFS and 0.1% for the 
landmark 4-year DFS. Other outcome analyses including OS, landmark OS 6 months after the 
start of trastuzumab, and sensitivity analyses for other survival endpoints were all 
congruent, demonstrating the non-inferiority of 6-months treatment. In addition, cardiac 
and other toxicities were reduced with 6-months treatment and therefore the balance of 
risk and benefit favours shorter treatment. It must be recognised that the patient 
population in PERSEPHONE, mapping onto standard practice in the clinic, had a significantly 
better profile of standard prognostic factors than patients treated in the original adjuvant 
trastuzumab trials2-5. The trial included 69% patients with ER-positive tumours compared 
with 36-54% in registration studies; 58% patients were node negative compared with 7-33%; 
and 47% had tumours ≤ 2cms compared with 35-40%. These standard prognostic factors are 
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similar to those for patients entered into PHARE and the other non-inferiority trials. 
PERSEPHONE recruited the number of patients specified in the statistical plan and with an 
event-driven analysis was sufficiently powered to meet the primary endpoint. PERSEPHONE 
is the largest trastuzumab duration comparison carried out in early breast cancer and the 
only one to demonstrate non-inferiority for the primary endpoint of reduced duration 
adjuvant trastuzumab. 
 
Prior to the set-up of the trial there was consensus from the PERSEPHONE TMG and the 
patient and public involvement (PPI) group, that an absolute difference up to 3% for the 6-
month treatment was considered acceptable by clinicians and patients. This is a margin 
commonly used in non-inferiority trials in oncology, including the recently published 
TAILORx study28. Approval for the trial from funders (NIHR HTA) with national and 
international peer-review, National Research Ethics Committee (REC) and each recruiting 
centre, endorsed the view that demonstrating this non-inferiority margin would be 
important, and if proven would be potentially practice changing. In the PERSEPHONE statistical 
analysis plan, we planned to calculate the HR limit of non-inferiority using the observed 4-year DFS 
in the standard arm at the time of the primary endpoint analysis. This statistical analysis plan was 
approved by the IDMSC as most appropriate for the study.  
 
Two other randomised studies compared 6 with 12 months, the HORG14 and PHARE12 trials.  
The HORG14 study included only 481 patients and employed a non-inferiority margin of 8% 
using dose-dense FEC followed by docetaxel as chemotherapy with 6 or 12 months 
trastuzumab commencing concurrently with docetaxel. This relatively small trial did not 
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demonstrate non-inferiority for 3-year DFS.  The PHARE Trial12 had an original recruitment 
target of 7,000 patients with a 2% non-inferiority margin. The trial included fewer patients 
than originally planned (n=3384) and reported an early primary endpoint of DFS at 2 years 
on the advice of the IDMSC. The HR non-inferiority limit was pre-specified at 1·15 on the 
expected standard arm DFS rate at 2 years of 85%. The trial reported a HR of 1·28 (95% CI 
1·05–1·56; non-inferiority p=0·29) and therefore failed to show non-inferiority. The longer 
term results from PHARE were very recently presented29 after a median of 7.5 years and the 
HR was 1·08 (95%CI, 0·93-1·25: non-inferiority p=0·39) with the upper confidence limit still 
exceeding the HR limit of 1·15. Therefore, the conclusion remained the same: non-inferiority 
was not confirmed. However the HR is now remarkably  similar to that seen in the 
PERSEPHONE trial. The PERSEPHONE and PHARE Trials Groups established a collaboration at 
the start of the trials for an individual-patient data meta-analysis / joint analysis, which will 
provide larger numbers for exploratory subgroup analyses.  
 
Long term follow-up of patients within the PERSEPHONE trial is planned. The importance of 
this in trials of HER2 positive breast cancer has been emphasised by a number of studies in 
which results have changed with longer follow-up. The PHARE Trial29 report after over 7 
years of follow-up shows a significant reduction in the HR for disease recurrence or death of 
6 months trastuzumab (HR 1.08) when compared with the 2 year results (HR 1.28). In 
contrast the FinHer study which provided the stimulus for all the reduced duration trials, 
demonstrated with longer follow up30 less effect in terms of the HR for disease recurrence 
or death which increased from 0.42 at 3 years, to 0.65 with a median follow-up time over 5 
years. In addition, a recent presentation from a combined analysis of the N9831 and NSABP 
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B31 studies31, shows that the risk of recurrence after 5 years is higher in ER+/HER2+ than 
ER-/HER2+ disease and this is relevant for PERSEPHONE because of the inclusion of a high 
percentage of ER positive patients.  Longer follow-up in the PERSEPHONE Trial will also be 
particularly important because changes in standard treatments during the trial mean that 
for concurrent, anthracycline with taxane-based, and neoadjuvant treatments there will be 
on average shorter follow-up for these subgroups of patients.  
 
Two trials tested 9 weeks concurrent treatment versus 12 months and neither 
demonstrated non-inferiority. SHORTHer15 randomised 1253 patients, the non-inferiority 
limit for a <3% margin below standard treatment was HR<1·29 for the primary endpoint of 
DFS at 5 years and the trial HR was 1·15 (90%CI 0·91, 1·46). SOLD16 randomised 2176 
patients, the non-inferiority limit for a <4% margin was HR<1·385 for the primary endpoint 
of DFS at 5-years and the trial showed HR was 1·39 (90%CI 1·12-1·72). One potential 
explanation is that the total dose of trastuzumab in the 9-week group is 20mg/kg which is 
significantly less than the 56mg/kg in PERSEPHONE, PHARE and HORG. This total dose may 
be insufficient to produce a non-inferior outcome compared to 12 months, even when used 
concurrently with docetaxel and sequenced immediately after surgery. 
 
Heterogeneities between pre-specified stratification subgroups are seen in the 
PERSEPHONE Trial. For DFS there is apparent heterogeneity (p<0·001) for timing of 
trastuzumab and chemotherapy; patients receiving concurrent treatment appeared to 
benefit more from standard 12 months trastuzumab. This is an intriguing result since we 
anticipated that concurrent rather than sequential timing of trastuzumab and 
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chemotherapy would demonstrate non-inferiority because of evidence of synergy of 
concurrent treatment from in vitro data32, and metastatic1 and adjuvant7,12,33 clinical trials. 
At the present time our demonstrated heterogeneity for trastuzumab scheduling and 
duration cannot be readily explained, but it is important to note that the decision to use 
concurrent or sequential treatment was selected by investigators and not randomised. 
Given that patients treated with concurrent chemotherapy also generally had more high risk 
features, it is not clear whether the observed heterogeneity is due to the treatment 
schedule per se, the type of chemotherapy used or whether it reflects the underlying risk of 
relapse. However, although the trial was stratified by concurrent and sequential 
chemotherapy and subgroups are balanced in terms of numbers of patients receiving either 
6 or 12 months trastuzumab, these groups are smaller, and therefore lack statistical power. 
All patients in the concurrent group received either anthracycline and taxane combinations 
or taxane based chemotherapy without anthracyclines. HERA 2,34 is the only trial reporting 
data for an exploratory subgroup analysis of a non-randomised comparison of sequential 
administration of trastuzumab after anthracycline and taxane, with trastuzumab after 
anthracycline without taxane chemotherapy. There is an interesting trend for less effect of 
trastuzumab in the anthracycline and taxane group, although this does not reach statistically 
significant levels of interaction. Whilst we acknowledge that any possible interaction 
between concurrent and sequential trastuzumab with chemotherapy may raise some 
concern, it is to be remembered that this subgroup analysis lacks statistical power for non-
inferiority.  The heterogeneity demonstrated for different chemotherapy backbones is 
driven mainly by the taxane without anthracycline group and this result should be 
interpreted with caution given the small size of this group and the very small number of 
events. For OS, heterogeneity is demonstrated in addition for ER status (p=0·02); patients 
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with ER negative disease appeared to benefit more from 12 months trastuzumab which is 
perhaps not surprising given the increased risk of relapse in this group.  
 
PERSEPHONE mapped onto standard practice in the UK and study strengths are broad 
inclusion criteria, which allowed recruitment of a large number of patients in routine clinics 
and ongoing recruitment as standard chemotherapy regimens and trastuzumab timing 
changed. The limitations of this design include the potential for complex interactions 
between trastuzumab duration and prognostic factors, the changing standard practice over 
the 8 years of the trial, the variable timing of randomisation potentially introducing 
ascertainment bias and selection of chemotherapy and trastuzumab timing according to 
perceived risk by the investigators i.e. concurrent preferred in higher risk patients (appendix 
pp2-4). An additional limitation that must be borne in mind is that the analyses were 
performed according to the intention-to-treat principle. While we believe that this is the 
most appropriate to use, ensuring unbiased estimates, it can potentially underestimate 
differences between treatment arms and thus drive the results towards non-inferiority. This 
is a concern particularly when adherence to treatment is low and/or differential loss to 
follow-up occurs. In that respect within the PERSEPHONE Trial, adherence to protocol-
mandated treatment is high and loss to follow-up is low. 
 
All reduced duration trastuzumab trials have demonstrated less cardiotoxicity for the 
shorter duration11,15,16. In addition, the HERA trial showed that 24 months of trastuzumab 
further increased rates of cardiotoxicity without improving cancer outcomes5,9. As part of 
the translational programme in PERSEPHONE over 80% of patients have donated blood 
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samples which will be part of a genome-wide association study of cardiotoxicity with 
investigation of interaction with duration of treatment.  
 
There have been significant changes to the management of HER2 positive early breast 
cancer over the past 13 years since neo/adjuvant trastuzumab was introduced and the 
concept for the PERSEPHONE trial was developed alongside the other duration trials. The 
trial was designed to be pragmatic, map onto standard practice, which allowed patients to 
continue to be enrolled as standard chemotherapy regimens and trastuzumab timings 
changed. Whilst this is an advantage for trial recruitment and ensures contemporaneity, one 
of the limitations of this design is that there will not be sufficient power in different 
subgroups to confirm non-inferiority. Following the report of N9831 in 2011 33 which 
demonstrated superiority of concurrent trastuzumab and taxane chemotherapy over 
sequential trastuzumab, there was increasing use of concurrent treatments. Up until 2011, 
the majority of patients in the UK received standard anthracycline-based regimens with 
sequential trastuzumab similar to those used successfully in HERA 2. The TCH (docetaxel, 
carboplatin, Herceptin) regimen from the BCIRG 006 study 4 and the APT (adjuvant 
paclitaxel and trastuzumab) 37 which avoid anthracyclines are now widely used in North 
America and are gaining in acceptance in Europe including the UK. The APT regimen was 
developed in particular for low risk node negative patients and tested in a phase II non-
randomised study. Our study includes only 403 (10%) patients, entered more recently, who 
received non-anthracycline containing regimens andin whom there have been very few 
events; therefore no conclusions can be drawn about the effect of a shorter duration in 
combination with a non-anthracycline regimen.  
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There have been additional advances in the management of HER2 positive early breast 
cancer which warrant consideration. Trials of neoadjuvant therapy can provide personalised 
HER2 directed therapies with potential for both escalation and de-escalation strategies. 
There has been increasing use of dual anti-HER2 therapy (trastuzumab and pertuzumab) 
with chemotherapy in the neoadjuvant setting following the Neo-SPHERE trial 38,39, which 
showed improved pCR rates and disease-free survival. In the recently published Katherine 
Trial 40, trastuzumab emtansine (TDM-1) was tested against trastuzumab after failure of 
neoadjuvant chemotherapy and anti-HER2 therapy to produce a complete pathological 
response (pCR). The estimated percentage of patients who were free of invasive disease at 3 
years was 88.3% in the T-DM1 group and 77.0% in the trastuzumab group. Invasive disease–
free survival was significantly higher in the T-DM1 group than in the trastuzumab group 
(hazard ratio for invasive disease or death, 0.50; 95% confidence interval, 0.39 to 0.64; 
P<0.001) 40. This significant improvement in outcomes is likely to lead to an appropriate 
escalation of standard treatment in the post-neoadjuvant setting, at least for patients who 
do not achieve pCR with neoadjuvant treatment. On the other hand, patients who do 
achieve a pCR could be considered for trials which are planned for de-escalation of HER2 
therapy. The APHINITY trial reported improved outcomes for the addition of 12 months 
adjuvant pertuzumab to 12 months trastuzumab. The reduction in disease recurrence was 
relatively small, albeit statistically significant35 (HR, 0·81; 95%CI 0·66-1·00; p=0·045) and 
subgroup analysis showed a larger effect for the node-positive subgroup. More precise 
prognostic/predictive classification is urgently required36 in order that the results of the de-
escalation trials and those escalating treatment with dual HER2 therapy35 can be 
appropriately applied to optimise effectiveness whilst reducing toxicity and containing cost. 
As part of the translational research programme within the PERSEPHONE trial over 80% of 
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patients have donated formalin-fixed paraffin embedded tumour tissue and germline 
bloods, and our aim is to investigate personalising trastuzumab duration taking into account 
germline and tumour genomics, as well as efficacy, toxicity and standard prognostic factors. 
 
In general, there remain very significant challenges to de-escalating effective treatments 
that have been used as standard for many years. There is likely to be an understandable 
reluctance on the part of both oncology teams and their patients to consider a change to 
practice which has been established since 2005, despite the potential benefit for the 
individual patient of reduced toxicity, length of treatment and a more rapid return to 
normal life. As we report the results of the PERSEPHONE trial, and reflect on the progress of 
our study from original concept to the present day, we are convinced that the optimal time 
to evaluate shorter durations is in registration trials, and we would strongly encourage such 
testing for new targeted adjuvant cancer therapies. Although we have demonstrated non-
inferiority for trastuzumab in the population we tested, there is ongoing discussion and 
intense debate about our results, including whether or not these are applicable in 2019 as 
compared with 2007 when the study was designed, due to the changes in standard 
treatments for HER2 positive breast cancer that have occurred. Duration questions within 
registration trials could only occur with significant high level international collaboration 
between the pharmaceutical industry, international academic groups, governments / 
medicines approval bodies such as the EMEA and FDA, with input from the wider cancer 
specialist teams and cancer patients, as has been discussed by Martine Piccart and her 
colleagues41. If shorter treatments are found to be non-inferior by agreed statistical criteria 
at the outset then these will become the standard of care on licensing. The escalating cost 
of effective novel anti-cancer treatments is rapidly becoming unsustainable even for 
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wealthy nations, and we believe clinical trials designed to test the non-inferiority of shorter 
treatments should become one of the priorities in cancer research. 
 
In conclusion, in the PERSEPHONE trial, we have demonstrated non-inferiority for 6 months 
adjuvant trastuzumab compared with 12 months in HER2-positive early breast cancer in the 
population treated. The observed absolute difference in the primary endpoint of DFS at 4 
years was only 0·4%. This result signals the potential of reducing treatment duration to 6 
months and thereby toxicity and cost whilst producing similar efficacy for at least some 
women with HER2 positive breast cancer. This trial provides a positive result and will 
stimulate significant debate since it is the only reduced duration study to demonstrate non-
inferiority for shorter adjuvant trastuzumab. 
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RESEARCH IN CONTEXT 
 
Evidence before the Study 
The benefit of adjuvant trastuzumab in HER2 positive breast cancer was established in 2005 
with the publication of two pivotal registration trials which both used 12 months 
trastuzumab and chemotherapy, compared with chemotherapy alone. Both HERA and a 
joint analysis of NSABP-B31 and NCCTG-N9831 demonstrated a significant improvement in 
disease-free survival (DFS). Shortly afterwards in 2006 the smaller FinHER trial (231 patients) 
published similar results for just 9 weeks trastuzumab given concurrently with docetaxel as 
the first definitive adjuvant treatment. This result prompted significant interest in de-
escalation trials to establish whether shorter duration trastuzumab could have similar 
efficacy. PERSEPHONE, PHARE and HORG tested 6 months against the standard 12 months, 
and SOLD and SHORTHer tested 9 weeks (given in a similar way to the FinHer protocol) 
versus 12 months.  
Added Value of this Study 
The Persephone Trial mapped onto standard practice in the UK and accepted patients who 
were planned to receive adjuvant trastuzumab and chemotherapy. Patients were 
randomised to 6 versus 12 months trastuzumab. The trial has a non-inferiority design and, 
with recruitment of 4088 patients, was powered to test that 6-months was no worse than 
3% below the standard disease-free survival (DFS) with 12 months treatment. Analysis 
following 512 DFS events showed a 4 year DFS of 89·4% with 6-months treatment and 89·8% 
with 12 months treatment. HR was 1·07 (90%CI 0·93–1·24, non-inferiority p=0·01) 
demonstrating non-inferiority for 6-months treatment. Persephone is the largest of the 
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reduced duration, adjuvant trastuzumab trials which recruited the required number of 
patients and accrued the number of events set out in the statistical analysis plan. This is the 
only trial to demonstrate non-inferiority in HER2 positive early breast cancer.  
Implications of all available evidence 
Available evidence for trastuzumab duration includes the SOLD and SHORTHer trials 
comparing 9 weeks trastuzumab to 12 months. Neither were able to demonstrate non-
inferiority, however, it is possible that 9 weeks trastuzumab is not a long enough duration to 
provide the benefit in outcomes seen with 12 months treatment. The smallest of the three 
trials comparing 6 months trastuzumab with 12 months was the 481-patient HORG trial 
which failed to demonstrate non-inferiority at the 8% level (HR=1·58 (95%CI 0·86-2·90). The 
3380-patient PHARE trial initially reported in 2013, and did not demonstrate non-inferiority 
at the 2% level (HR=1·28 (95%CI 1·05-1·56)). However, this trial was recently presented with 
longer follow-up and results showing a HR of 1·08 (95%CI 0·93-1·25) which are remarkably 
similar to the 4088-patient PERSEPHONE’s findings (HR=1·07 (90%CI 0·93-1·24). During the 
time the trial recruited over 8 years there were changes in standard practice supported by 
randomised evidence which included use of trastuzumab concurrently with chemotherapy 
rather than sequentially and the introduction of non-anthracycline based chemotherapy 
from BCIRG 006. There was also non-randomised evidence for non-anthracycline de-
escalated chemotherapy in better risk patients (APT and docetaxel / cyclophosphamide). 
During the trial standard treatments gradually changed in the clinic. PERSEPHONE 
demonstrates non-inferiority for 6 months trastuzumab in the early disease setting and we 
believe this result should signal the possibility of reduced duration trastuzumab in HER2 
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positive patients.  However, the study does not have the statistical power to address the 
duration question for any specific chemotherapy regimen or sub-group.  
 
DATA SHARING 
Data collected within the PERSEPHONE study will be made available to researchers whose 
full proposal for their use of the data has been approved by the Persephone Trial 
Management Group and whose research group includes a qualified statistician. The data 
required for the approved, specified purposes and the trial protocol will be provided, after 
completion of a data sharing agreement. Data sharing agreements will be set up by the 
sponsors of the trial, the funders, the trial coordination centre, and the Trial Steering and 
Management Groups. The data will be made available 2 years after publication. Please 
address requests for data to: 
 persephone@live.warwick.ac.uk 
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Table 1: Baseline characteristics, split by randomised group 
Characteristic 12-month 
group 
(N=2045) 
6-month 
group 
(N=2043) 
Total 
(N=4088) 
ER status *    
     Negative 633 (31%) 632 (31%) 1265 (31%) 
     Positive 1412 (69%) 1411 (69%) 2823 (69%) 
Chemotherapy type *    
     Anthracycline based 854 (42%) 846 (41%) 1700 (42%) 
     Taxane based 200 (10%) 203 (10%) 403 (10%) 
     Anthracycline + Taxane based 989 (48%) 991 (49%) 1980 (48%) 
     No taxane and no anthracycline 2 (<1%) 3 (<1%) 5 (<1%) 
Chemotherapy timing *    
     Adjuvant 1737 (85%) 1731 (85%) 3468 (85%) 
     Neoadjuvant 308 (15%) 312 (15%) 620 (15%) 
Trastuzumab timing *    
     Concurrent 951 (47%) 952 (47%) 1903 (47%) 
     Sequential 1094 (53%) 1091 (53%) 2185 (53%) 
Age at randomisation    
     Median (range) 56 (23-82) 56 (23-83) 56 (23-83) 
     <35 years old 50 (2%) 45 (2%) 95 (2%) 
     35 – 49 years old 552 (27%) 557 (27%) 1109 (27%) 
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     50 – 59 years old 608 (30%) 656 (32%) 1264 (31%) 
     60 + 835 (41%) 785 (39%) 1620 (40%) 
Nodal Status at surgery [of the 3468 adjuvant patients]    
     Negative 1003 (58%) 1019 (59%) 2022 (58%) 
     1–3 nodes positive 479 (28%) 486 (28%) 965 (28%) 
     4+ nodes positive 244 (14%) 211 (12%) 455 (13%) 
     Unknown 11 (<1%) 15 (<1%) 26 (<1%) 
Tumour size ^ [of the 3468 adjuvant patients]    
     <=2cm 824 (47%) 807 (47%) 1631 (47%) 
     >2 and <=5cm 778 (45%) 786 (45%) 1564 (45%) 
     >5cm 87 (5%) 83 (5%) 170 (5%) 
     Unknown 48 (3%) 55 (3%) 103 (3%) 
Tumour Grade ^    
     I (well diff.) 29 (1%) 34 (2%) 63 (2%) 
     II (mod. diff.) 628 (31%) 642 (31%) 1270 (31%) 
     III (poor diff.) 1322 (65%) 1297 (64%) 2619 (64%) 
     Unknown 66 (3%) 70 (3%) 136 (3%) 
Ethnicity    
     White 1658 (81%) 1648 (81%) 3306 (81%) 
     Asian 57 (3%) 52 (3%) 109 (3%) 
     Black 52 (3%) 45 (2%) 97 (2%) 
     Other 17 (<1%) 21 (1%) 38 (1%) 
     Unknown 261 (13%) 277 (13%) 538 (13%) 
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Menopausal status before chemotherapy    
     Pre 567 (28%) 580 (29%) 1147 (28%) 
     Peri 110 (5%) 150 (7%) 260 (6%) 
     Post 1144 (56%) 1070 (52%) 2214 (54%) 
     Not assessable/Not available 224 (11%) 243 (12%) 467 (12%) 
Reported prior use of cardiac medication    
     Yes 44 (2%) 55 (3%) 99 (2%) 
     No 2001 (98%) 1988 (97%) 3989 (98%) 
IHC
+
-score and FISH† positivity    
     3+ 1460 (71%) 1487 (73%) 2947 (72%) 
     2+ and FISH† positive 540 (27%) 497 (24%) 1037 (25%) 
     Not available 45 (2%) 59 (3%) 104 (3%) 
* Stratification variable 
^ of largest invasive tumour at diagnosis 
+
 IHC = Immunohistochemistry 
† FISH = Fluorescence in situ hybridization 
6 men are included in the 4088 patients: 4 in the 12-month group and 2 in the 6-month group. 
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Table 2: Details of Events 
Number of patients with a recorded … 12-month 
group  
(N=2045) 
6-month 
group 
(N=2043) 
Total 
 
(N=4088) 
Death 156 (8%) 179 (9%) 335 (8%) 
Breast cancer listed as a cause 129 (83%) 143 (80%) 272 (81%) 
Breast cancer not listed as a cause, but a local or distant relapse reported 2 (1%) 6 (3%) 8 (2%) 
Breast cancer not listed as a cause and no local or distant relapse reported 25 (16%) 30 (17%) 55 (17%) 
    
Relapse * 218 (11%) 234 (11%) 452 (11%) 
Local relapse 79 (4%) 77 (4%) 156 (4%) 
Distant relapse 183 (9%) 190 (9%) 373 (9%) 
    
Relapse or Death 247 (12%) 265 (13%) 512 (13%) 
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Second Primary 58 (3%) 52 (3%) 110 (3%) 
* Patients can have both a local and distant relapse recorded 
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Table 3: Adverse Events and Cardiac Monitoring, over the two 6-month periods 
 12-month group 6-month group 
Number of patients reporting at least one 
incidence of -  Overall In months 1-6 In months 7-12 Overall In months 1-6 In months 7-12 
Adverse event with severe& CTCAE grade 459/1894 (24%) 350/1894 (18%) 259/1764 (15%) 373/1939 (19%) 370/1939 (19%) 8/93 (9%) 
SAR to trastuzumab $ 64/2044 (3%) 39/2044 (2%) 25/2019^ (1%) 29/2041 (1%) 28/2041 (1%) 2/2015^ (0·1%) 
       
Clinical cardiac dysfunction # 224/1968 (11%) 164/1968 (8%) 157/1936 (8%) 155/1994 (8%) 126/1994 (6%) 96/1894 (5%) 
Stopped trastuzumab permanently due to 
cardiac toxicity 
 
146/1894 (8%) 63/1894 (3%) 83/1764 (5%) 61/1939 (3%) 60/1939 (3%) 1/93 (1%) 
Cardiac death † 
Cardiac death related to trastuzumab † 
7/2044 
0/2044 
0/2044 
0/2044 
 0/2019^ 
0/2019^ 
4/2041 
0/2041 
0/2041 
0/2041 
0/2015^ 
0/2015^ 
       
Low LVEF * 228/2040 (11%) 148/2040 (7%) 151/1938 (8%) 176/2038 (9%) 146/2038 (7%) 84/1749 (5%) 
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Significant falls in LVEF       
Absolute decrease of >=10% from baseline 
to <50% 
163/1959 (8%) 98/1950 (5%) 102/1873 (5%) 132/1959 (7%) 102/1954 (5%) 60/1693 (4%) 
LVEF<50% after a baseline of >=59% 108/1959 (6%) 63/1950 (3%) 71/1873 (4%) 86/1959 (4%) 70/1954 (4%) 32/1693 (2%) 
       
 
& CTCAE grade >=3, or 2 for palpitations 
$ Denominators exclude the 3 patients known not to have received Trastuzumab 
^ Denominators reduced due to either deaths or withdrawal of consent for follow-up within the 1st 6 months.# Clinical cardiac dysfunction = Symptoms of 
cardiac disease, and / or signs of congestive heart failure and / or new medication for cardiac disease 
† 11 deaths were reported to have a ‘cardiac’ cause, either first cause or contributory. None occurred during the first 12 months after starting trastuzumab 
treatment. 9 patients died with no metastatic disease, and 2 had metastatic disease. In all cases trastuzumab was judged to be unrelated / unlikely to be 
related to cardiac problems 
* Low LVEF = Number of patients with at least one LVEF<50%, or LVEF % unknown but classified on report as abnormal  
Abbreviations: 
SAR – Serious Adverse Reaction  
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LVEF = Left Ventricular Ejection Fraction 
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Figures in the Manuscript 
Figure 1: Trial profile 
Figure 2: Kaplan-Meier Plots of Disease-Free Survival (Panel A) and Overall Survival (Panel B), 
according to Randomised Group 
Figure 3: Forest plots of Disease-Free Survival for all patients (Panel A) and adjuvant only patients 
(Panel B) 
Figure 4: Kaplan-Meier Plots of Disease-Free Survival (Panel A) and Overall Survival (Panel B) from 
the landmark analysis from 6 months of Trastuzumab treatment, according to Randomised Group 
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4089 Patients underwent randomization 
28 (1·4%) Patients lost to follow-up 
61 (3·0%) Withdrew from follow-up schedule 
 
2045 were included in the primary endpoint analysis 
29 (1·4%) Patients lost to follow-up 
38 (1·9%) Withdrew from follow-up schedule 
 
2043 were included in the primary endpoint analysis 
1941/2043 (95%) Patients included in treatment analysis 
 
1738/1941 (90%) Received exact randomized treatment 
 
• 2 Received no trastuzumab (HER2 negative; metastatic) 
• 1846 (95%) Received 1–9 doses of trastuzumab 
• 93 (5%) Received 10+ doses of trastuzumab 
1895/2045 (93%) Patients included in treatment analysis 
 
1556/1895 (82%) Received exact randomized treatment 
 
• 1 Received no trastuzumab (cardiac toxicity) 
• 130 (7%) Received 1–9 doses of trastuzumab 
• 1764 (93%) Received 10+ doses of trastuzumab 
7 Ineligible 
• 4 with previous cancer/DCIS treated with surgery + RT 
• 2 HER2 negative 
• 1 with primary cancer confined to the axilla 
12 Ineligible 
• 7 with previous cancer/DCIS treated with surgery + RT 
• 1 HER2 negative 
• 2 with metastatic disease 
• 1 having received >9 doses of Trastuzumab 
• 1 double randomised (excluded from analysis) 
2045 Were assigned to  
12 months of Trastuzumab Treatment 
2044 Were assigned to  
6 months of Trastuzumab Treatment 
DCIS: ductal carcinoma in situ   RT: radiotherapy 
Figure 1:  Trial profile 
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Figure 4 A: Kaplan-Meier Plots of Disease-Free Survival from the landmark analysis from 6 months of Trastuzumab treatment,  
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Figure 4 B: Kaplan-Meier Plots of Overall Survival from the landmark analysis from 6 months of Trastuzumab treatment,  
according to Randomised Group 
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